Amphiphilic cyclobutenes and cylobutanes

A pharmaceutical composition comprising a compound of Formula (I):

• or a pharmaceutically acceptable salt thereof,
• wherein:
• ---- represents an optionally present double bond;
• R1 and R2 are independently selected from the group consisting of:
• H, halo, OR5, and =0;
• R3 is an optionally substituted C5-C40 alkyl;
• R4 is C1-C40 alkyl optionally substituted with Cy1, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo, C1-6 haloalkyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)NRc1Rd1, C(═NRe1)NRc1Rd1, NRc1C(═NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1 S(O)2Rb1 and S(O)2NRc1Rd1;
• each Cy1 is independently C6-10 aryl, C3-10 carbocyclyl, 5-10 membered heteroaryl or 4-10 membered heterocyclyl, each of which is unsubstituted or substituted by 1, 2, 3, 4 or 5 substituents independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(═NRe1)NRc1Rd1, NRc1C(═NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, S(O)2NRc1Rd1 and oxo;
• each Ra1, Rb1, Rc1, Rd1, is independently selected from C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 carbocyclyl, 5-10 membered heteroaryl, 4-10 membered heterocyclyl, C6-10 aryl-C1-4 alkyl, C3-10 carbocyclyl-C1-4 alkyl, (5-10 membered heteroaryl)-C1-4 alkyl or (4-10 membered heterocyclyl)-C1-4 alkyl, wherein said C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-10 carbocyclyl, 5-10 membered heteroaryl, 4-10 membered heterocyclyl, C6-10 aryl-C1-4 alkyl, C3-10 carbocyclyl-C1-4 alkyl, (5-10 membered heteroaryl)-C1-4 alkyl and (4-10 membered heterocyclyl)-C1-4 alkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NR4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NR4Rd4, NRc4C(O)Rb4, NRc4C(O)NR4Rd4, NRc4C(O)ORa4, C(═NRe4)NR4Rd4, NRc4C(═NRe4)NR4Rd4 S(O)Rb4, S(O)NR4Rd4, S(O)2Rb4 NRc4S(O)2Rb4, NRc4S(O)2NR4Rd4 and S(O)2NR4Rd4;
• each Ra4, Rb4, Rc4 and Rd4 is independently selected from H, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl and C2-4 alkynyl, wherein said C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-4 haloalkyl, and C1-4 haloalkoxy;
• and
• Z is selected from the group consisting of:
• COR6, CO2H, CONR6, OCOR6, OR6, SR6, NR6R7, and OPO3R6;
• R5 is C1-C6 alkyl;
• R6 and R7 are independently H or C1-C6 alkyl;
• and
• wherein the hydrocarbon backbone formed by R4 and R3—Z is amphiphilic
• and a pharmaceutically acceptable carrier.

A method for treating a mycobacterial infection in a patient, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula (I):

• or a pharmaceutically acceptable salt thereof,
• wherein:
• ----- represents an optionally present double bond;
• R1 and R2 are independently selected from the group consisting of:
• H, halo, OR5, and ═O;
• R3 is absent or is an optionally substituted C1-C40 alkyl;
• R4 is H or an optionally substituted C1-C40 alkyl;
• and
• Z is selected from the group consisting of:
• COR6, C02R6, CONR6, OCOR6, OR6, SR6, NR6R7, and OPO3R6;
• R5 is H or C1-C6 alkyl;
• R6 and R7 are independently H or C1-C6 alkyl;
• wherein the backbone formed by R4 and R3—Z is amphiphilic.